AVALO THERAPEUTICS, INC. (AVTX) Operating cash flow 2016–2025
AVALO THERAPEUTICS, INC. (AVTX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$51.5MFY2025 · since FY2016: -$14.6M → -$51.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$51.5M | -4.9% |
| FY2024 | -$49.1M | -59.9% |
| FY2023 | -$30.7M | -14.7% |
| FY2022 | -$26.8M | +62.3% |
| FY2021 | -$70.9M | -74.9% |
| FY2020 | -$40.5M | -111.9% |
| FY2019 | -$19.1M | -511.7% |
| FY2018 | -$3.1M | -124.9% |
| FY2017 | $12.6M | +186.3% |
| FY2016 | -$14.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More AVTX financial trends
AVTX RevenueAVTX Net incomeAVTX Net marginAVTX Gross profitAVTX Gross marginAVTX Operating incomeAVTX Operating marginAVTX Free cash flowAVTX Capital expendituresAVTX Return on equityAVTX Stock buybacksAVTX Dividends paidAVTX Total assetsAVTX Total liabilitiesAVTX Shareholders’ equityAVTX overview →